Anesthesia in malignant hyperthermia susceptible patients

Area of Science:

• Anesthesiology
• Pharmacology
• Genetics

Background:

• Malignant hyperthermia (MH) is a severe pharmacogenetic disorder of skeletal muscle.
• Patients with MH susceptibility require careful anesthetic management to prevent potentially fatal hypermetabolic crises.
• Previous anesthetic techniques have been associated with MH episodes, necessitating the evaluation of safer alternatives.

Purpose of the Study:

• To evaluate the safety and reliability of specific anesthetic techniques in patients with known malignant hyperthermia susceptibility.
• To assess the perioperative course of patients undergoing general and regional anesthesia without prophylactic dantrolene.
• To provide detailed anesthetic management strategies for MH-susceptible patients.

Main Methods:

• Retrospective analysis of 30 general and 3 regional anesthetics in 27 MH-susceptible patients.
• Monitoring of vital signs (ECG, temperature, blood pressure, oxygen saturation, end-tidal pCO2).
• Use of specific anesthetic agents and supportive care, excluding prophylactic dantrolene.

Main Results:

• No malignant hyperthermia-related changes in heart rate, body temperature, or creatine kinase (CK) levels were observed.
• No other symptoms indicative of MH crisis occurred during the intra- or postoperative period.
• The anesthetic techniques employed were found to be safe and reliable for MH-susceptible individuals.

Conclusions:

• The anesthetic management strategies detailed in this study appear safe and effective for patients with malignant hyperthermia susceptibility.
• Avoidance of prophylactic dantrolene did not lead to adverse MH events with the described anesthetic protocols.
• Further research into anesthetic management for MH-susceptible patients is warranted.